ReviewF1000Research2020
Recent advances in understanding and managing cutaneous T-cell lymphomas.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.Journal for immunotherapy of cancer · 2021Pooled it
- Psychological Resilience and Quality of Life in Mycosis Fungoides Patients: A BIO-MUSE Study.Acta dermato-venereologica · 2026Article
- Review
- IQDMA disrupts STAT5 nuclear transport through CDC42-PAK2 axis collapse in cutaneous T-cell lymphoma.Frontiers in immunology · 2026Article
- The dual burden of a rare cancer: psychosocial impact of disease symptoms and unmet care needs in cutaneous T-cell lymphoma.Frontiers in psychology · 2026Article
- Squamous Cell Carcinoma Arising Within a Mycosis Fungoides Plaque: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Photodynamic Therapy in Primary Cutaneous Skin Lymphoma-Systematic Review.Journal of clinical medicine · 2025Review
- The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.Biomedicines · 2025Article
- Spatial cell graph analysis reveals skin tissue organization characteristic for cutaneous T cell lymphoma.NPJ systems biology and applications · 2024Article
- Cutaneous Squamous Cell Carcinoma Arising Within a Previously Irradiated Mycosis Fungoides Lesion.Cureus · 2024Article
- Targeting TAG-72 in cutaneous T cell lymphoma.Heliyon · 2024Article
- Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review.Cureus · 2024Review
- Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.JMIR research protocols · 2024Article
- Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice.Disease models & mechanisms · 2023Article
- An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas.Pharmaceutics · 2023Review
- Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma.Cancers · 2023Review
- Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma.Dermatology and therapy · 2023Article
- The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.The Journal of investigative dermatology · 2022Article
- Micellar Curcumin Substantially Increases the Antineoplastic Activity of the Alkylphosphocholine Erufosine against TWIST1 Positive Cutaneous T Cell Lymphoma Cell Lines.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients' health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.